Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.56 |
| ▸ | PPARA | Q07869 | 6/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984209 | 0.99 | PPARG (0.55) | PPARGPPARAPTPN1CYP2C9KCNH2 | |
| Hydrochloric Acid SCHEMBL3984019 | 0.99 | PPARG (0.55) | PPARGPPARAPTPN1CYP2C9KCNH2 | |
| SCHEMBL3984016 | 0.90 | PPARG (0.52) | PPARGPPARAPTPN1CYP2C9KCNH2 | |
| SCHEMBL3984210 | 0.89 | PPARG (0.51) | PPARGPPARAPTPN1CYP2C9KCNH2 | |
| SCHEMBL2520539 | 0.84 | FFAR1 (0.64) | PPARGPPARAMAPTFFAR1TP53 | |
| SCHEMBL27636490 | 0.84 | TP53 (0.56) | PPARGPPARAPTPN1CYP2C9KCNH2 | |
| SCHEMBL27855543 | 0.83 | PPARG (0.53) | PPARGPPARAPTPN1CYP2C9KCNH2 | |
| SCHEMBL9260216 | 0.83 | PPARG (0.53) | PPARGPPARAPTPN1CYP2C9KCNH2 | |
| SCHEMBL2524843 | 0.82 | PPARG (0.51) | PPARGPPARAPTPN1CYP2C9KCNH2 | |
| SCHEMBL2524840 | 0.82 | PPARG (0.51) | PPARGPPARAPTPN1CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221336-A1 | Pparalpha/Gamma Agonists and Processes of Preparing | GARRETT CHRISTINE E | 2008-09-11 | — | — | US | disclosed |
| US-20080221336-A1 | Pparalpha/Gamma Agonists and Processes of Preparing | GARRETT CHRISTINE E | 2008-09-11 | — | — | US | disclosed |
| EP-1912978-A2 | PPAR / AGONISTS AND PROCESSES OF PREPARING | Novartis AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007009080-A2 | PPAR [ALPHA/GAMMA] AGONISTS AND PROCESSES OF PREPARING | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007009080-A2 | PPAR [ALPHA/GAMMA] AGONISTS AND PROCESSES OF PREPARING | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221336-A1 | Pparalpha/Gamma Agonists and Processes of Preparing | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885PTPN1 2288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.